Ginsenoside F1 attenuates pirarubicin-induced cardiotoxicity by modulating Nrf2 and AKT/Bcl-2 signaling pathways

BACKGROUND: Pirarubicin (THP) is an anthracycline antibiotic used to treat various malignancies in humans. The clinical usefulness of THP is unfortunately limited by its dose-related cardiotoxicity. Ginsenoside F1 (GF1) is a metabolite formed when the ginsenosides Re and Rg1 are hydrolyzed. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yang, Ma, Jiulong, Liu, Shan, Chen, Chen, Li, Qi, Qin, Meng, Ren, Liqun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834006/
https://www.ncbi.nlm.nih.gov/pubmed/36644383
http://dx.doi.org/10.1016/j.jgr.2022.06.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834006/
https://www.ncbi.nlm.nih.gov/pubmed/36644383
http://dx.doi.org/10.1016/j.jgr.2022.06.002

Ejemplares similares